Sign in

NCT04868396Active, not recruiting

Patient-derived Glioma Stem Cell Organoids

Glioma Stem Cell Organoids: Preclinical Model of Glioblastoma Heterogeneity to Explore Resistance Mechanisms to Conventional Treatment Schedules.

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemotherapy. Tumor recurrence is inevitable after which life prolonging therapies are no longer available. The development of new treatments for GM is being hampered by inter-and intratumoral heterogeneity of tumors and their microenvironment, which currently cannot be predicted accurately with current diagnostics. Objective: To establish primary patient derived organoid cultures from GM to study mechanisms that contribute to aggressive tumor growth and treatment resistance in primary and recurrent GM. Study design: Preclinical study, using patient derived glioblastoma tissue. Study population: Patients 18 years or older, with newly diagnosed glioblastoma. Main study parameters/endpoints: Intra-and inter organoid genetic and epigenetic heterogeneity that is representative for GM. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Minimal burden, since the biopsies are part of a regular neurosurgical procedure (debulking); which intends to eradicate the macroscopical tumorload in order to optimize survival benefit. The tissue (biopsy) that will be used for this trial is part of the tumor tissue that is resected during the standard debulking. Benefit: no benefit for the patient.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
60 (estimated)
First submitted
26 Apr 2021
Start date
10 Apr 2021
Primary completion date
1 Jan 2027
Lead sponsor
Maastricht Radiation Oncology
Diseases
Glioblastoma
NCT number
NCT04868396

What you commit to

  • Study type: Observational
  • Planned participants: 60
  • From 10 Apr 2021 to the primary completion date, 1 Jan 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Neurosurgical contraindications for gross total resection

Other illness

  • Clotting disorders

Other

  • Karnofsky index \< 70

Who the study is looking for

  • MRI imaging suggestive for glioblastoma
  • \> 18 years of age

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Maastricht UMC
Coordinator of this site? Confirm its status
MaastrichtNetherlandsUnknown status
Maastricht Radiation Oncology
Coordinator of this site? Confirm its status
MaastrichtNetherlandsUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.